Represented a public biotechnology company for their licensing and supply agreement related to the commercialization rights of tadalafil. Foley handled the IP due diligence and agreement work while evaluating challenging risk factors, including patents that were involved in an ongoing litigation at the time of the deal. The deal received the 2009 Deal of Distinction Award in the Health Care Sector by the Licensing Executives Society (USA & Canada) for “a clear demonstration of the power of courage and creativity in licensing.”